Non-Opioid Pain Patch Market Report 2026

Non-Opioid Pain Patch Market Overview

• Non-Opioid Pain Patch market size has reached to $3.63 billion in 2025 • Expected to grow to $4.69 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Non-Opioid Pain Patch Market Growth Fueled By Escalating Prevalence Of Chronic Pain • Market Trend: Latigo Biotherapeutics Launches LTG-001, A Genetically Targeted Non-Opioid Pain Relief Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Opioid Pain Patch Market?

Non-opioid pain patch refers to a topical pain treatment that is non-opioid, non-systemic, and considered the only treatment available to provide prescription strength. It administers non-addictive medication directly to the pain area via the skin, providing effective pain management while minimizing the risk of addiction and the side effects linked to opioid use. It is used to relieve mild to moderate pain. The main non-opioid pain patches are lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches refer to a transdermal patch having analgesic action made of synthetic amide-type anesthetic lidocaine in a 5 percent aqueous base solution, which is used to aid in treating some skin disorders' itching and pain. They are distributed by hospital pharmacies, retail pharmacies, and other channels for the treatment of various indications including musculoskeletal pain and neuropathic pain.

What Is The Non-Opioid Pain Patch Market Growth Forecast?

The non-opioid pain patch market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising chronic pain prevalence, increased regulatory support for non-opioid therapies, advancements in transdermal drug delivery technology, growing patient awareness of addiction-free treatments, expansion into neuropathic pain indications. Major trends in the forecast period include rising preference for non-addictive pain management, growing adoption of topical and localized therapies, expansion of over-the-counter and prescription hybrid patches, increased demand for chronic pain management solutions, innovation in patch adhesion and drug delivery duration.

What Is The Driver Of The Non-Opioid Pain Patch Market?

The rising prevalence of chronic pain is expected to propel the growth of the non-opioid pain patch market going forward. Chronic pain refers to severe pain that lasts for an extended period or coexists with another medical condition. Non-opioid pain patches are used to relieve mild to moderate pain and treat headaches, muscle aches, arthritis, backaches, and other types of pain. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, an estimated 24.3% of adults experienced chronic pain in 2023, with 8.5% amounting to roughly one-third of those affected reporting high-impact chronic pain, and women showing higher prevalence than men. Therefore, the rising prevalence of chronic pain is propelling the non-opioid pain patch industry.

Key Players In The Global Non-Opioid Pain Patch Market

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

Global Non-Opioid Pain Patch Market Trends and Insights

Major companies operating in the non-opioid pain patch market are developing innovative products such as genetically validated targets medicine. Genetically validated targets medicine involves developing drugs that target biological pathways directly linked to disease, based on strong genetic evidence. This approach enhances treatment effectiveness and reduces the risk of side effects. For instance, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company launched the LTG-001. It is a selective inhibitor of the Nav1.8 sodium channel, which is primarily expressed in peripheral nerve cells. By targeting this specific channel, LTG-001 aims to block pain signals at their source, potentially providing effective pain relief without affecting the central nervous system. The Phase 1 clinical trial results indicated that LTG-001 has a Tmax (time to maximum concentration) of approximately 1.5 hours, suggesting a rapid onset of pain relief. This feature is particularly important for both acute and chronic pain management. LTG-001 is designed for oral administration, making it convenient for patients compared to injectable or topical treatments. This route of delivery can enhance compliance and ease of use.

What Are Latest Mergers And Acquisitions In The Non-Opioid Pain Patch Market?

In January 2024, Heron Therapeutics a US-based biotechnology company that manufactures non-opioid pain medicine partnered with CrossLink Life Sciences. The aim of the partnership is to expand the sales network for ZYNRELEF, a pain-reducing solution for orthopedic surgeries, across the US. This collaboration seeks to increase product adoption, streamline access, and improve post-operative pain management for more patients. CrossLink Life Sciences is a US-based private orthopedic, spine, and sports medicine device distributorship.

What Defines the Non-Opioid Pain Patch Market?

The non-opioid pain patch market consists of sales of aspirin, ibuprofen, and acetaminophen patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Opioid Pain Patch Market Report 2026?

The non-opioid pain patch market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain patch industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.